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Abstract
Interpretation of variants present in complete genomes or exomes reveals
numerous sequence changes, only a fraction of which are likely to be
pathogenic. Mutations have been traditionally inferred from allele frequencies
and inheritance patterns in such data. Variants predicted to alter mRNA splicing
can be validated by manual inspection of transcriptome sequencing data,
however this approach is intractable for large datasets. These abnormal mRNA
splicing patterns are characterized by reads demonstrating either exon
skipping, cryptic splice site use, and high levels of intron inclusion, or
combinations of these properties. We present, Veridical, an  method forin silico
the automatic validation of DNA sequencing variants that alter mRNA splicing.
Veridical performs statistically valid comparisons of the normalized read counts
of abnormal RNA species in mutant versus non-mutant tissues. This leverages
large numbers of control samples to corroborate the consequences of
predicted splicing variants in complete genomes and exomes.
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      Amendments from Version 1
We appreciate the feedback received from the reviewers and 
we feel that the manuscript has been improved as a result. The 
following major revisions have been incorporated:
•	 Figure	1	has	been	abbreviated	according	to	the	advice	of	the	
reviewers.
•	 Figure	2	is	new.	It	illustrates	the	details	of	the	data	used	to	
infer different types of splicing events.
•	 We	have	re-formulated	the	equations	in	the	methods	section	
pertaining to the definitions of the various validating reads, 
as	requested	by	reviewers,	and	we	reference	each	formal	
definition in the text.
•	 We	have	clearly	demarcated	the	performance	information	
and	have	added	sub-headings	to	improve	the	readability	of	
our results section.
•	 We	have	coloured	all	mutant	reads	in	the	IGV	images	to	more	
clearly depict every validating read and its type.
•	 We	have	added	paragraphs	to	the	Discussion	pertaining	to:
○	 Achieving sample size sufficiency via power analysis
○	 Clarifying	that	Veridical	does	not	attempt	to	predict	
alternative splicing events
○	 Clarifying our usage of the term “validation”
We	have	also	updated	the	Veridical	software,	as	follows:
It	now	outputs	p-values	to	four	(instead	of	two)	decimal	places.
This	allows	for	more	precise	post-hoc	filtering	and	can	allow	one	to	
apply	more	stringent	thresholds,	as	recently	advocated	(Johnson	
Proc.	Natl.	Acad.	Sci.	110:	19313–7,	2013).
The correct behavior of allowing a variant to be present in the 
filtered set is to check if there are any strongly corroborating, 
statistically significant, results. Previously, the filtered output file 
would	only	consider	the	p-value	of	the	splicing	consequence	of	
highest	frequency.	This	has	been	fixed.
Strongly	corroborating	reads	are	defined	as:	any	junction-
spanning-based	evidence	or	read-abundance-based	intron	
inclusion	(refer	to	the	manuscript	for	more	details).
We noticed that variants with a statistically significant number of 
intron inclusion with mutation reads were erroneously placed into 
the filtered set, despite the overall number of intron inclusion reads 
not having achieved statistical significance. We have resolved this 
regression.
None	of	the	changes	to	Veridical,	nor	the	aforementioned	
regressions, affected any of the results presented in our 
manuscript.	For	a	more	detailed	explanation	of	the	revisions	made	
please refer to the referees’ comments and our respective replies.
See referee reports
REVISED
be the most frequent cause of hereditary disease6. Computational 
identification of mRNA splicing mutations within DNA sequenc-
ing (DNA-Seq) data has been implemented to varying degrees of 
sensitivity, with most software only evaluating conservation solely 
at the intronic dinucleotides adjacent to the junction (i.e.7). Other 
approaches are capable of detecting significant mutations at other 
positions with constitutive, and in certain instances, cryptic, splice 
sites5,8,9 which can result in aberrations in mRNA splicing. Presently, 
only information theory-based mRNA splicing mutation analysis 
has been implemented on a genome scale10. Splicing mutations can 
abrogate recognition of natural, constitutive splice sites (inactivat-
ing mutation), weaken their binding affinity (leaky mutation), or 
alter splicing regulatory protein binding sites that participate in 
exon definition. The abnormal molecular phenotypes of these muta-
tions comprise: (a) complete exon skipping, (b) reduced efficiency 
of splicing, (c) failure to remove introns (also termed intron reten-
tion or intron inclusion), or (d) cryptic splice site activation, which 
may define abnormal exon boundaries in transcripts using non- 
constitutive, proximate sequences, extending or truncating the exon. 
Some mutations may result in combinations of these molecular 
phenotypes. Nevertheless, novel or strengthened cryptic sites can 
be activated independently of any direct effect on the corresponding 
natural splice site. The prevalence of these splicing events has been 
determined by ourselves and others5,11–13. The diversity of possible 
molecular phenotypes makes such aberrant splicing challenging to 
corroborate at the scale required for complete genome (or exome) 
analyses. This has motivated the development of statistically robust 
algorithms and software to comprehensively validate the predicted 
outcomes of splicing mutation analysis.
Putative splicing variants require empirical confirmation based on 
expression studies from appropriate tissues carrying the mutation, 
compared with control samples lacking the mutation. In mutations 
identified from complete genome or exome sequences, correspond-
ing transcriptome analysis based on RNA sequencing (RNA-Seq) 
is performed to corroborate variants predicted to alter splicing. 
Manually inspecting a large set of splicing variants of interest with 
reference to the experimental samples’ RNA-Seq data in a program 
like the Integrative Genomics Viewer (IGV)14, or simply perform-
ing database searches to find existing evidence would be time- 
consuming for large-scale analyses. Checking control samples 
would be required to ensure that the variant is not a result of alterna-
tive splicing, but is actually causally linked to the variant of interest. 
Manual inspection of the number of control samples required for sta-
tistical power to verify that each displays normal splicing would be 
laborious and does not easily lend itself to statistical analyses. This 
may lead to either missing contradictory evidence or to discarding a 
variant due to the perceived observation of statistically insignificant 
altered splicing within control samples. In addition, a list of puta-
tive splicing variants returned by variant prediction software can 
often be extremely large. The validation of such a significant quan-
tity of variants may not be feasible, for example, in certain types of 
cancer, in instances where the genomic mutational load is high and 
only manual annotation is performed. We have therefore developed 
Veridical, a software program that automatically searches all given 
experimental and control RNA-Seq data to validate DNA-derived 
splicing variants. When adequate expression data are available at the 
locus carrying the mutation, this approach reveals a comprehensive 
Introduction
DNA variant analysis of complete genome or exome data has typi-
cally relied on filtering of alleles according to population frequency 
and alterations in coding of amino acids. Numerous variants of 
unknown significance (VUS) in both coding and non-coding gene 
regions cannot be categorized with these approaches. To address 
these limitations, in silico methods that predict biological impact of 
individual sequence variants on protein coding and gene expression 
have been developed, which exhibit varying degrees of sensitivity 
and specificity1. These approaches have generally not been capable 
of objective, efficient variant analysis on a genome-scale.
Splicing variants, in particular, are known to be a significant cause 
of human disease2–5 and indeed have even been hypothesized to 
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set of genes exhibiting mRNA splicing defects in complete genomes 
and exomes. Veridical and its associated software programs are 
available at: www.veridical.org.
Methods
The program Veridical was developed to allow high-throughput val-
idation of predicted splicing mutations using RNA sequencing data. 
Veridical requires at least three files to operate: a DNA variant file 
containing putative mRNA splicing mutations, a file listing of cor-
responding transcriptome (RNA-Seq) BAM files, and a file annotat-
ing exome structure. A separate file listing RNA-Seq BAM files for 
control samples (i.e. normal tissue) can also be provided. Here, we 
demonstrate the capabilities of the software for mutations predicted 
in a set of breast tumours. Veridical compares RNA-Seq data from 
the same tumours with RNA-Seq data from control samples lack-
ing the predicted mutation. However, in principle, potential splicing 
mutations for any disease state with available RNA-Seq data can be 
investigated. In each tumour, every variant is analyzed by checking 
the informative sequencing reads from the corresponding RNA-Seq 
experiment for non-constitutive splice isoforms, and comparing 
these results with the same type of data from all other tumour and 
normal samples that do not carry the variant in their exomes.
Veridical concomitantly evaluates control samples, providing for 
an unbiased assessment of splicing variants of potentially diverse 
phenotypic consequences. Note that control samples include all 
non-variant containing files (i.e. RNA-Seq files for those tumours 
without the variant of interest), as well any normal samples pro-
vided. Increasing the number of the set of control samples, while 
computationally more expensive, increases the statistical robust-
ness of the results obtained.
For each variant, Veridical directly analyzes sequence reads aligned 
to the exons and introns that are predicted to be affected by the 
genomic variant. We elected to avoid indirect measures of exon 
skipping, such as loss of heterozygosity in the transcript, because 
of the possibility of confusion with other molecular etiologies (i.e. 
deletion or gene conversion), unrelated to the splicing mutations. 
The nearest natural site is found using the exome annotation file 
provided, based upon the directionality of the variant, as defined 
within Table 1. The genomic coordinates of the neighboring exon 
boundaries are then found and the program proceeds, iterating 
over all known transcript variants for the given gene. A diagram 
of this procedure is provided in Figure 1. The variant location, 
Pertinent Splice Site
A B Strand Direction
Exonic Donorα + →
Exonic Donorα - ←
Intronic Acceptorβ + ←
Intronic Acceptorβ - →
 α	–	5′ splice site                        β	–	3′ splice site    
Table 1. Definitions used within Veridical to 
determine the direction in which reads are 
checked. A and B represent natural site positions, 
defined in Figure	1(B).
Figure 1. Diagram	portraying	the	definitions	used	within	Veridical	to	
specify genic variant position and read coordinates. We employ the 
same	conventions	as	IGV14. Blue lines denote genes, wherein thick 
lines represent exons and thin lines represent introns.
C, is specifically referring to the variant itself. JC refers to the 
variant-induced location of the predicted mRNA splice site, which 
is often proximate to, but distinct from the coordinate of the actual 
genomic mutation itself.
The program uses the BamTools API15 to iterate over all of the 
reads within a given genomic region across experimental and con-
trol samples. Individual reads are then assessed for their corrobo-
rating value towards the analysis of the variant being processed, 
as outlined in the flowchart in Figure 3. Validating reads are based 
on whether they alter either the location of the splice junction (i.e. 
junction-spanning) or the abundance of the transcript, particularly 
in intronic regions (i.e. read-abundance). Junction-spanning reads 
contain DNA sequences from two adjacent exons or are reads that 
extend into the intron (Equation 1(e)). These reads directly show 
whether the intronic sequence is removed or retained by the spli-
ceosome, respectively. Read-abundance validated reads are based 
upon sequences predicted to be found in the mutated transcript in 
comparison with sequences that are expected to be excised from 
the mature transcript in the absence of a mutation (Equation 1(f)). 
Both types of reads can be used to validate cryptic splicing, exon 
skipping, or intron inclusion. A read is said to corroborate cryptic 
splicing if and only if the variant under consideration is expected to 
activate cryptic splicing. Junction-spanning, cryptic splicing reads 
are those in which a read is exactly split from the cryptic splice site 
to the adjacent exon junction (Equation 1(a)). For read-abundance 
cryptic splicing, we define the concept of a read fraction, which 
is the ratio of the number of reads corroborating the cryptically 
spliced isoform and the number of reads that do not support the use 
of the cryptic splice site (i.e. non-cryptic corroborating) in the same 
(      )
(      )
blue red
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genomic region of a sample. Cryptic corroborating reads are those 
which occur within the expected region where cryptic splicing 
occurs (i.e. spliced-in regions). This region is bounded by the vari-
ant splice site location and the adjacent (direction dependent) splice 
junction (Equation 1(a)). Non-cryptic corroborating reads, which 
we also term “anti-cryptic” reads, are those that do not lie within 
this region, but would still be retained within the portion that would 
be excised, had cryptic splicing occurred (Equation 1(b)). To iden-
tify instances of exon skipping, Veridical only employs junction-
spanning reads. A read is considered to corroborate exon skipping 
if the connecting read segments are split such that it connects two 
exon boundaries, skipping an exon in between (Equation 1(c)). A 
read is considered to corroborate intron inclusion when the read 
is continuous and either overlaps with the intron-exon boundary 
(and is then said to be junction-spanning) or if the read is within 
an intron (and is then said to be based upon read-abundance). We 
only consider an intron inclusion read to be junction spanning if it 
spans the relevant splice junction, A. Equation 1(d) formalizes this 
concept. We occasionally use the term “total intron inclusion” to 
denote that any such count of intron inclusion reads includes both 
those containing and not containing the mutation itself. Graphical 
examples of some of these validation events, with a defined variant 
location, are provided in Figure 2.
We proceed to formalize the above descriptions as follows. A given 
read is denoted by r, with start and end coordinates (r
s
, r
e
), if the 
read is continuous, or otherwise, with start and end coordinate pairs, 
(r
s1
, r
e1
) and (r
s2
, r
e2
) as diagrammed within Figure 2. Let ℓ be the 
length of the read. The set ζ denotes the totality of validating reads. 
The criterion for r ∈ ζ is detailed below. It is important to note that 
validating reads are necessary but not sufficient to validate a vari-
ant. Sufficiency is achieved only if the number of validating reads is 
statistically significant relative to those present in control samples. 
ζ itself is partitioned into three sets: ζ
c
, ζ
e
, and ζi for evidence of 
cryptic splicing, exon skipping, and intron inclusion, respectively. 
We allow partitions to be empty. Let JC denote the adjacent splice junction, and let B denote the downstream natural site, as defined 
by Figure 2 and Table 1. Without loss of generality, we consider 
only the red (i.e. direction is right) set of labels within Figure 1(B), 
as further typified by Figure 2. Then the (splice consequence) parti-
tions of ζ are given by:
r ∈ ζ
c
 ⇔ variant is cryptic ∧ (rs2 – re1 = B
– JC ∨ (rs > JC ∧ re < A))     
(1a)
r ∉ ζ
c
 ∧ variant is cryptic ∧ ¬ ( r
s2
 – r
e1
 = B – JC)
⇒ r ∈ anti-cryptic     (1b)
r ∈ ζ
e
 ⇔ (r
e1
= D ∧ r
s2
 = E)     (1c)
r ∈ ζi ⇔ (A∈ [rs, re]) ∨ ((A ∉ [rs, re])
∧ r
s
 > A – ℓ ∧ r
e
 < B ∧ ¬ (A ∈ [r
s
, r
e
]))   (1d)
Figure 2. Illustrative	examples	of	aberrant	splicing	detection.	Grey	
lines denote reads, wherein thick lines denote a read mapping to 
genomic	sequence	and	thin	lines	represent	connecting	segments	
of	 reads	 split	 across	 spliced-in	 regions	 (i.e.	 exons	 or	 included	
introns).	 Dotted	blue rectangles denote portions of genes which 
are spliced out in a mutant transcript, but are otherwise present 
in a normal transcript. Mutant reads are purple	if	they	are	junction-
spanning and green	 if	they	are	read-abundance	based.	Start	and	
end	coordinates	of	reads	with	two	portions	are	denoted	by	(r
s1
, r
e1
)	
and	(r
s2
, r
e2
),	while	coordinates	of	 those	with	only	a	single	portion	
are	denoted	by	(r
s
, r
e
).	Refer	to	the	caption	of	Figure	1 for additional 
graphical element descriptions.
(      )
(      )
(      )
yel-
low
green
purple
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Figure 3. The	algorithm	employed	by	Veridical	 to	validate	variants.	Refer	 to	Table	1 for definitions concerning direction and Figure	1 for 
variable	depictions.	B	is	defined	as	follows:	B	(B	site	left	(←)	of	A ⇒ B := D. B	site	right	(→)	of	A ⇒ B := E.
Splice  site 
type
Compute 
expected 
alignment gap
E = |C - B|
Compute 
observed 
alignment 
gap O from 
read
Compare
E and O
Increment 
junction 
spanning 
cryptic 
splicing count
Cryptic
Compute 
expected 
alignment gap
E = |E - D|
Natural
Equal
Not equal
Check if read is within the expected 
region for cryptic splicing
Increment 
read 
abundance 
cryptic 
splicing 
corroborating 
count
Read is between ‘B’ and ‘C’
Increment 
read 
abundance 
cryptic 
splicing 
contradicting 
count
Read is between ‘A’ and ‘C’
Compute 
observed 
alignment gap 
O from read
Compare
E and O
Check for gaps in read 
alignment
Increment 
junction 
spanning 
exon 
skipping 
count
Equal
Not equal
All increment operations 
increment the eld 
pertaining to either an 
experimental or control 
sample, depending 
upon where the read 
originated.
Get next read’s 
details . Retrieved 
reads are at least 
partially between
D and E
Check if there are 
more transcripts for the 
variant’s gene
Unchecked transcripts exist
Check 
read with 
respect to 
next 
transcript
Checked all transcripts
Not equal
Check if any part of the read is 
intronic 
Does not have alignment gaps
Check if the read 
overlaps the intron-exon 
boundary
Read is between ‘A’ and ‘B’ (or overlaps either )
Increment read 
abundance intron 
inclusion count
No overlap
Increment junction 
spanning intron 
inclusion count
Overlaps
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The program outputs two tables, along with summaries thereof. 
The first table lists all validated read counts across all categories 
for experimental samples, while the second table does the same for 
the control samples. P-values are shown in parentheses within the 
experimental table, which refer to the column-dependent (i.e. the 
read type is given in the column header) p-value for that read type 
with respect to that same read type in control samples. The program 
produces three files: a log file containing all details regarding vali-
dated variants, an output file with the programs progress reports and 
summaries, and a filtered validated variant file. The filtered file con-
tains all validated variants of statistical significance (set as p < 0.05, 
by default), defined as variants with one or more validating reads 
achieving statistical significance in a strongly corroborating read 
type. These categories are limited to all junction-spanning based 
splicing consequences and read-abundance total intron inclusion. 
For example, a cryptic variant for which p = 0.04 in the junction-
spanning cryptic column would meet this criteria, assuming the 
default significance threshold.
The p-values given by Veridical are more robust when the program 
is provided with a large number of samples. The minimum sample 
size is dependent upon the desired power, α value, and the effect 
size (ES). The minimum samples size could be computed as fol-
lows: 
2 2
2
 =  σ zN ES . For α = 0.05 and β = 0.2 (for a power of 0.8): z = 
2.4865 for the one-tailed test. Then, 2 222.4865 =   σN ES . Ideally, Veridical 
could be run with a trial number of samples.
Then, one would compute effect sizes from Veridical’s output. The 
standard deviation in the above formula could also be estimated 
from one’s data, although it should be transformed using Yeo-
Johnson (such as via an appropriate R package) before computing 
this estimation.
We elected to use RefSeq19 genes for the exome annotation, as 
opposed to, the more permissive exome annotation sets, UCSC 
Known Genes20 or Ensembl21. The large number of transcript variants 
within Ensembl, in particular, caused many spurious intron inclu-
sion validation events. This occurred because reads were found to be 
intronic in many cases, when in actuality they were exonic with 
respect to the more common transcript variant. In addition, the inclu-
sion of the large number of rare transcripts in Ensembl significantly 
increased program run-time and made validation events much more 
challenging to interpret unequivocally. The use of RefSeq, which 
is a conservative annotation of the human exome, resolves these 
issues. It is possible that some subset of unknown or Ensemble 
annotated intronic transcripts could be sufficiently prevalent to merit 
inclusion in our analysis. We do not attempt to perform the difficult 
task of deciding which of these transcripts would be worth using. 
Indeed, the task of confirming and annotating of such transcripts is 
already done by the more conservative annotation we employ.
We also provide an R program22 which produces publication quality 
histograms displaying embedded Q-Q plots and p-values, to evalu-
ate for normality of the read distribution and statistical significance, 
respectively. The R program performs the YJ transformation as 
implemented in the car package23. The histograms generated by the 
program use the Freedman-Draconis24 rule for break determination, 
We separately partition ζ by its evidence type, the set of junction-
spanning reads, δ and read-abundance reads, α:
r ∈ δ ⇔ (A ∈ [r
s
, r
e
]) ∨ (r ∈ ζ
c
 ∧ r
s2 – re1 = B – JC)  (1e)
r ∈ α ⇔ r ∉ δ      (1f)
Once all validating reads are tallied for both the experimental and 
control samples, a p-value is computed. This is determined by com-
puting a z-score upon Yeo-Johnson (YJ)16 transformed data. This 
transformation, shown in Equation 2, ensures that the data is suf-
ficiently normally distributed to be amenable to parametric testing.
 
2
( 1) 1 if 0  0
log( 1) if 0  0
( , ) (2)
( 1) 1
if  < 0  2
2
log( 1) if  < 0  2
x x
x x
x
x x
x x
λ
λ
λ
λ
 λ
ψ λ
λ
λ
 λ
−
 + − ≥ ∧  ≠
+ ≥ ∧  =
= 
− + −
− ∧  ≠
−
− − + ∧  =
The transform is similar to the Box-Cox power transformation, but 
obviates the requirement of inputting strictly positive values and 
has more desirable statistical properties. Furthermore, this transfor-
mation allowed us to avoid the use of non-parametric testing, which 
has its own pitfalls regarding assumptions of the underlying data 
distribution17. We selected λ = 1–2, because Veridical’s untransformed 
output is skewed left, due to their being, in general, less validating 
reads in control samples and the fact that there are, by design, vastly 
more control samples than experimental samples. We found that 
this value for λ generally made the distribution much more nor-
mal. A comparison of the distributions of untransformed and trans-
formed data is provided in Figure S1. We were not concerned about 
small departures from normality as a z-test with a large number of 
samples is robust to such deviations18.
Thus, we can compute the p-value of the pairwise unions of the two 
sets of partitions of ζ, except the irrelevant ζ
e
 ∪ α = Ø. We only 
provide p-values for these pairwise unions and do not attempt to 
provide p-values for the partitions for the different consequences of 
the mutations on splicing. While such values would be useful, we 
do not currently have a robust means to compute them. Our previ-
ous work provides guidance on interpretation of splicing mutation 
outcomes3–5,10. Thus for ζ
x
 ∈ {ζ
c
, ζ
e
, ζi}, let ΦZ (z) represent the 
cumulative distribution function of the one-sided (right-tailed — 
i.e. P[X > x]) standard normal distribution. Let N represent the total 
number of samples and let V represent the set of all ζ
x
 validations, 
across all samples. Then:
 
1 2
1
1 ( )
| ζ | ( ( , ))
N
j N
j
j
j
V
V V
N N
xz p z
µ σ
µ ψ
σ
=
=
= = −
−
= = Φ
∑
∑
2
1
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within the supplementary methods of the TCGA paper26. Accordingly, 
the following examples demonstrate the utility of Veridical to iden-
tify potentially pathogenic mutations from a much larger subset of 
predicted variants.
Input, output, and explanatory files for Veridical
5 Data Files 
http://dx.doi.org/10.6084/m9.figshare.894971 
Leaky Mutations
Mutations that reduce, but not abolish, the spliceosome’s ability to 
recognize the intron/exon boundary are termed leaky3. This can lead 
to the mis-splicing (intron inclusion and/or exon skipping) of many 
but not all transcripts. An example, provided in Figure 4, displays 
a predicted leaky mutation (chr5:162905690G>T) in the HMMR 
gene in which both junction-spanning exon skipping (p < 0.01) 
and read-abundance-based intron inclusion (p = 0.04) are observed. 
We predict this mutation to be leaky because its final Ri exceeds 
1.6 bits — the minimal individual information required to recog-
nize a splice site and produce correctly spliced mRNA4. Indeed, 
the natural site, while weakened by 2.16 bits, remains strong — 
10.67 bits. This prediction is validated by the variant-containing 
sample’s RNA-Seq data (Figure 4), in which both exon skipping 
(5 reads) and intron inclusion (14 reads, 12 of which are shown, 
versus an average of 4.051 such reads per control sample) are 
observed, along with 70 reads portraying wild-type splicing. Only 
a single normally spliced read contains the G→T mutation. These 
results are consistent with an imbalance of expression of the two 
and the Q-Q plots use algorithm Type 8 for their quantile function, 
as recommended by Hyndman and Fan25. This program is embed-
ded within a Perl script, for better integration into our workflow. 
Lastly, a Perl program was implemented to automatically retrieve 
and correctly format an exome annotation file from the UCSC 
database20 for use in Veridical. All data use hg19/GRCh37, however 
when new versions of the genome become available, this program 
can be used to update the annotation file.
Results
Veridical validates predicted mRNA splicing mutations using high-
throughput RNA sequencing data. We demonstrate how Veridical 
and its associated R program are used to validate predicted splicing 
mutations in somatic breast cancer. Each example depicts a particu-
lar variant-induced splicing consequence, analyzed by Veridical, 
with its corresponding significance level. The relevant primary 
RNA-Seq data are displayed in IGV, along with histograms and 
Q-Q plots showing the read distributions for each example. The 
source data are obtained from controlled-access breast carcinoma 
data from The Cancer Genome Atlas (TCGA)26. Tumour-normal 
matched DNA sequencing data from the TCGA consortium was used 
to predict a set of splicing mutations, and a subset of corresponding 
RNA sequencing data was analyzed to confirm these predictions 
with Veridical. Overall, 442 tumour samples and 106 normal 
samples were analyzed. Briefly, all variants used as examples in 
this manuscript came from running the matched TCGA exome files 
(to which the RNA-Seq data corresponds) through SomaticSniper27 
and Strelka28 to call somatic mutations, followed by the Shannon 
Human Splicing Pipeline10 to find splicing mutations, which served 
as the input to Veridical. Details of the RNA-Seq data can be found 
Figure 4. IGV	images	depicting	a	predicted	leaky	mutation	(chr5:162905690G>T)	within	the	natural	acceptor	site	of	exon	12	(162905689–
162905806)	of	HMMR. This gene has four transcript variants and the given exon number pertains to isoforms a and b	(reference	sequences	
NM_001142556 and NM_012484).	RNA-Seq	reads	are	shown	in	the	centre	panel.	The	bottom	blue	track	depicts	RefSeq	genes,	wherein	
each blue rectangle denotes an exon and blue	connecting	lines	denote	introns.	In	the	middle	panel,	each	rectangle	(grey	by	default)	denotes	
an	aligned	read,	while	thin	lines	are	segments	of	reads	split	across	exons.	Red	and	blue	coloured	rectangles	in	the	middle	panel	denote	
aligned	 reads	of	 inserts	 that	are	 larger	or	smaller	 than	expected,	 respectively.	Reads	are	highlighted	by	 their	splicing	consequence,	as	
follows:	cryptic	splicing	(green),	exon	skipping	(purple),	junction-spanning	intron	inclusion	(dark green),	and	read-abundance	intron	inclusion	
(cyan).	(A)	depicts	a	genomic	region	of	chromosome	5:	162902054–162909787.	The	variant	occurs	in	the	middle	exon.	Intron	inclusion	can	
be	seen	in	this	image,	represented	by	the	reads	between	the	first	and	middle	exon	(since	the	direction	is	left,	as	described	within	Table	1).	
These	14	reads	are	read-abundance-based,	since	they	do	not	span	the	intron-exon	junction.	(B)	depicts	a	closer	view	of	the	region	shown	in	
(A)	—	162905660–162905719.	The	dotted	vertical	black	lines	are	centred	upon	the	first	base	of	the	variant-containing	exon.	The	thin	lines	in	
the	middle	panel	that	span	the	entire	exon	fragment	are	evidence	of	exon	skipping.	These	5	reads	are	split	across	the	exon	before	and	after	
the	variant-containing	exon,	as	seen	in	(A).
(A) (B)
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mutation (chr1:985377C>T) within the AGRN gene. The concordance 
between the splicing outcomes generated by these mutations and 
the Veridical results indicates that the proposed method detects both 
mutations that inactivate splice sites and cryptic splice site activation.
Cryptic Mutations
Recurrent genetic mutations in some oncogenes have been reported 
among tumours within the same, or different, tissues of origin. 
Common recurrent mutations present in multiple abnormal sam-
ples are recognized by Veridical. This avoids including a variant- 
containing sample among the control group, and outputs the results 
of all of the variant-containing samples. A relevant example is shown 
in Figure 7. The mutation (chr1:46726876G>T) causes activation 
of a cryptic splice site within RAD54L in multiple tumours. Upon 
computation of the p-values for each of the variant-containing 
tumours, relative to all non-variant containing tumours and nor-
mal controls, not all variant-containing tumours displayed splicing 
abnormalities at statistically significant levels. Of the six variant-
containing tumours, two had significant levels of junction-spanning 
intron inclusion, and one showed statistically significant read-
abundance-based intron inclusion. Details for all of the aforemen-
tioned variants, including a summary of read counts pertaining to 
each relevant splicing consequence, for experimental versus control 
samples, are provided in Table 2.
Figure 5. Histogram	of	read-abundance-based	intron	inclusion	with	embedded	Q-Q	plots	of	the	predicted	leaky	mutation	(chr5:162905690G>T)	
within HMMR, as shown in Figure	4.	The	arrowhead	denotes	the	number	of	reads	(14	in	this	case)	in	the	variant-containing	file,	which	is	more	
than	observed	in	the	control	samples	(p =	0.04).
alleles, as expected for a leaky variant. Figure 5 shows that for the 
distribution of read-abundance-based intron inclusion is marginally 
statistically significant (p = 0.04).
Inactivating Mutations
Variants that inactivate splice sites have negative final Ri values3 
with only rare exceptions4, indicating that splice site recognition 
is essentially abolished in these cases. We present the analysis of 
two inactivating mutations within the PTEN and TMTC2 genes 
from different tumour exomes, namely: chr10:89711873A>G and 
chr12:83359523G>A, respectively. The PTEN variant displays 
junction-spanning exon skipping events (p < 0.01), while the TMTC2 
gene portrays both junction-spanning and read-abundance-based 
intron inclusion (both splicing consequences with p < 0.01). In 
addition, all intron inclusion reads in the experimental sample con-
tain the mutation itself, while only one such read exists across all 
control samples analyzed (p < 0.01). The PTEN variant contains 
numerous exon skipping reads (32 versus an average of 2.466 such 
reads per control sample). The TMTC2 variant contains many junction-
spanning intron inclusion reads with the G→A mutation (all of its 
junction-spanning intron inclusion reads: 22 versus an average of 
0.002 such reads per control sample). IGV screenshots for these 
variants are provided within Figure 6. This figure also shows an 
example of junction-spanning cryptic splice site activated by the 
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Figure 6. (A)	 depicts	 an	 inactivating	 mutation	 (chr10:89711873A>G)	 within	 the	 natural	 acceptor	 site	 of	 exon	 6	 (89711874–89712016)	
of PTEN.	 The	dotted	vertical	black	 line	denotes	 the	 location	of	 the	 relevant	 splice	site.	The	 region	displayed	 is	89711004–89712744	on	
chromosome	10.	Many	of	the	32	exon	skipping	reads	are	evident,	typified	by	the	thin	lines	in	the	middle	panel	that	span	the	entire	exon.	
There	is	also	a	substantial	amount	of	read-abundance-based	intron	inclusion,	shown	by	the	reads	to	the	left	of	the	dotted	vertical	line.	Exon	
skipping	was	statistically	significant	(p	<	0.01),	while	read-abundance-based	intron	inclusion	was	not	(p	=	0.53).	Panels	(B)	and	(C)	depict	
an	inactivating	mutation	(chr12:83359523G>A)	within	the	natural	donor	site	of	exon	6	(83359338–83359523)	of	TMTC2.	(B)	depicts	a	closer	
view	(83359501–83359544)	of	the	region	shown	in	(C)	and	only	shows	exon	6.	Some	of	the	22	junction-spanning	intron	inclusion	reads	can	
be	seen.	In	this	case,	all	of	these	reads	contain	the	mutation,	shown	by	the	green adenine base in each read, between the two vertical dotted 
lines.	(C)	depicts	a	genomic	region	of	chromosome	12:	83359221–83360885,	TMTC2	exons	6–7.	The	variant	occurs	in	the	left	exon.	65	read-
abundance-based	intron	inclusion	can	be	seen	in	this	image,	represented	by	the	reads	between	the	two	exons.	Panel	(D)	depicts	a	mutation	
(chr1:985377C>T)	causing	a	cryptic	donor	 to	be	activated	within	exon	27	 (the	 second	 from	 left,	 985282–985417)	of	AGRN. The region 
displayed	is	984876–985876	on	chromosome	1	(exons	26–29	are	visible).	Some	of	the	34	cryptic	(junction-spanning)	reads	are	portrayed.	
The	dotted	black	vertical	 line	denotes	the	cryptic	splice	site,	at	which	cryptic	reads	end.	The	read-abundance-based	intron	 inclusion,	of	
which	two	reads	are	visible,	was	not	statistically	significant	(p	=	0.68).	Refer	to	the	caption	of	Figure	4	for	IGV	graphical	element	descriptions.
Performance
The performance of the software is affected by the number of pre-
dicted splicing mutations, the number of abnormal samples contain-
ing mutations and control samples and the corresponding RNA-Seq 
data for each type of sample. Veridical has the ability to analyze 
approximately 3000 variants in approximately 4 hours, assuming an 
input of 100 BAM files of RNA-Seq data. The relationship between 
time and numbers of BAM files and variants are plotted in Figure 8 
for a 2.27 GHz processor. Veridical uses memory in linear propor-
tion to the number and size of the input BAM files. In our tests, 
(A) (B)
(C) (D)
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Figure 7. IGV	images	and	their	corresponding	histograms	with	embedded	Q-Q	plots	depicting	all	six	variant-containing	files	with	a	mutation	
(chr1:46726876G>T)	which,	in	some	cases,	causes	a	cryptic	donor	to	be	activated	within	the	intron	between	exons	7	and	8	of	RAD54L. This 
results	in	the	extension	of	the	downstream	natural	donor	(the	5′	end	of	exon	8).	This	gene	has	two	transcript	variants	and	the	given	exon	
numbers pertain to isoform a	(reference	sequence	NM_003579).	Only	samples	IV	and	V	have	statistically	significant	intron	inclusion	relative	
to	controls.	read-abundance-based	intron	inclusion	can	be	seen	in	(A),	between	the	two	exons.	The	region	displayed	is	on	chromosome	1:	
46726639–46726976.	(B)	depicts	the	corresponding	histogram	for	the	15	read-abundance-based	intron	inclusion	reads	(p	=	0.05)	that	are	
present	in	sample	IV.	The	intron-exon	boundary	on	the	right	is	the	downstream	natural	donor.	(C)	typifies	some	of	the	13	junction-spanning	
intron	inclusion	reads	that	are	a	direct	result	of	the	intronic	cryptic	site’s	activation.	In	these	instances,	reads	extending	past	the	intron-exon	
boundary	are	being	spliced	at	the	cryptic	site,	instead	of	the	natural	donor.	In	particular,	samples	IV	and	V	both	have	a	statistically	significant	
numbers	of	such	reads,	7	(p	=	0.01)	and	5	(p	=	0.04),	respectively.	This	is	further	typified	by	the	corresponding	histogram	in	(D).	(C)	focuses	
upon	exon	8	from	(A)	and	displays	the	genomic	positions	46726908–46726957.	Refer	to	the	caption	of	Figure	4	for	IGV	graphical	element	
descriptions.	In	the	histograms,	arrowheads	denote	numbers	of	reads	in	the	variant-containing	files.	The	bottom	of	the	plots	provide	p-values	
for each respective arrowhead. Statistically significant	p-values	and	their	corresponding	arrowheads	are	denoted	in	red.
(A) (B)
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Gene Chr Cv Cs Variant Type
Initial 
Ri 
Final 
Ri 
ΔRi # SC ET p-value RE RT RN Rμ Figure
HMMR chr5 162905690 162905689 G/T Leaky 12.83 10.67 -2.16 ES JS <		0.01 5 11 0 0.020 4, 5 
II RA 0.04 14 2133 103 4.051
PTEN chr10 89711873 89711874 A/G Inactivating 12.09 -2.62 -14.71 ES JS <		0.01 32 975 386 2.466	 6(A) 
TMTC2 chr12 83359523 83359524 G/A Inactivating 1.74 -1.27 -3.01 II JS <		0.01 22 2241 383 4.754 6(B) 
II JSwM <	0.01 22 0 1 0.002
II RA <	0.01 65 7293 1395 15.739 6(C) 
AGRN chr1 985377 985376 C/T Cryptic -2.24 4.79 7.03 CS JS <		0.01 34 97 23 0.217 6(D) 
RAD54L chr1 46726876 46726895 G/T Cryptic 13.4 14.84 1.44 I II JS N/A 0 645 58 1.274 7 
II RA 0.54 3 2171 290 4.458
II II JS 0.51 1 645 58 1.274
II RA 0.33 6 2171 290 4.458
III II JS N/A 0 645 58 1.274
II RA 0.33 6 2171 290 4.458
IV II JS 0.01 7 645 58 1.274
II RA 0.05 15 2171 290 4.458
V II JS 0.04 5 645 58 1.274
II RA N/A 0 2171 290 4.458
VI II JS N/A 0 645 58 1.274
II RA N/A 0 2171 290 4.458
Table 2. Examples of variants validated by Veridical and their selected read types. Header abbreviations Chr, C
v
, C
s
, #, SC, and ET, denote 
chromosome,	variant	coordinate,	splice	site	coordinate,	sample	number	(where	applicable),	splicing	consequence,	and	evidence	type,	
respectively.	Headers	containing	R	with	some	subscript	denote	numbers	of	validated	reads	for	the	specified	variant’s	splicing	consequence(s)	
and	evidence	type(s).	RE	denotes	reads	within	variant-containing	tumour	samples.	RT and RN denote control samples, for tumours and normal 
cells, respectively. Rμ is the per sample mean of RT and RN.	Splicing	consequences:	CS	denotes	cryptic	splicing,	ES	denotes	exon	skipping,	and	
II	denotes	intron	inclusion.	Evidence	types:	JS	denotes	junction-spanning	and	RA	denotes	read-abundance.
Figure 8. Profiling	data	for	Veridical	runtime.	Tests	were	conducted	upon	an	Intel	Xeon	@	2.27	GHz.	Visualizations	were	generated	with	R22 
using Lattice30 and Effects31.	A	surface	plot	of	time	vs.	numbers	of	BAM	files	and	variants	is	provided	in	(A).	Effect	plots	are	given	in	(B)	and	
demonstrate	the	effects	of	the	numbers	of	BAM	files	and	variants	upon	runtime.	The	effect	plots	were	generated	using	a	linear	regression	
model	(R 2 =	0.7525).
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allows for manual inspection to discover samples that contained the 
alternative splicing pattern, and consequently, permits the identifi-
cation of DNA mutations in the same location which went unde-
tected during genome sequencing.
The statistical power of Veridical is dependent upon the quality of 
the RNA-Seq data used to validate putative variants. In particular, a 
lack of sufficient coverage at a particular locus will cause Veridical 
to be unable to report any significant results. A coverage of at least 
20 reads should be sufficient. This estimate is based upon alternative 
splicing analyses in which this threshold was found to imply con-
cordance with microarray and RT-PCR measurements32–35. There 
are many potential legitimate reasons why a mutation may not be 
validated: (a) A lack of gene expression in the variant containing 
tumour sample, (b) nonsense-mediated decay may result in a loss 
of expression of the entire transcript, (c) the gene itself may have 
multiple paralogs and reads may not be unambiguously mapped, 
(d) other non-splicing mutations could account for a loss of expres-
sion, and (e) confounding natural alternative splicing isoforms may 
result in a loss of statistical significance during read mapping of the 
control samples. The prevalence of loci with insufficient data is 
dependent upon the coverage of the sequencing technology used. As 
sequencing technologies improve, the proportion of validated muta-
tions is expected to increase. Such an increase would mirror that 
observed for the prevalence of alternative splicing events36. In addi-
tion, mutated splicing factors can disrupt splicing fidelity and exon 
definition37. This effect could decrease Veridical’s ability to validate 
splicing mutations affected by a disruption of the definition of the 
pertinent exon. Veridical does not currently form any equivalence 
between distinct variants affecting the same splice site. Such vari-
ants will be analyzed independently. Veridical is intended to be used 
with RNA-Seq data that not only corresponds to matched DNA-Seq 
data, but also only for sets of samples with comparable sequencing 
protocols, since the non-normalized comparisons performed rely 
upon the evening out of batch effects, due to a substantial number 
of control samples. It is important to note that acceptance of the 
null hypothesis, due to an absence of evidence required to disprove 
it, does not imply that the underlying prediction of a mutation at a 
particular locus is incorrect, but merely that the current empirical 
methods employed were insufficient to corroborate it.
“Validate,” in the present context, refers to the condition where 
sufficient statistical evidence has been marshaled in support of a 
variant. However, the threshold for significance can vary so these 
analyses can also be thought of as strongly corroborating variants. 
Recent studies in Bayesian statistics have suggested that a p-value 
threshold of 0.05 does not correspond to strong support of the alter-
native hypothesis. Accordingly, Johnson38 recommends the use of 
tests at the 0.005 or 0.001 level of significance.
We consider alternative splicing to be a different problem. Veridical 
does not aim to identify putatively pathogenic variants, but rather, 
to confirm existing in silico predictions thereof. We do infer exon 
skipping events (i.e. alternative splicing) de novo, but only to cata-
log dysregulated splicing “phenotypes” due to genomic sequence 
variants. This is not the first study to use a large control dataset. 
Indeed the Variant Annotation, Analysis & Search Tool (VAAST)39 
using RNA-Seq BAM files with an average size of approximately 
6 GB, Veridical used approximately 0.7 GB for ten files to 1 GB 
for 100 files.
Discussion
We have implemented Veridical, a software program that automates 
confirmation of mRNA splicing mutations by comparing sequence 
read-mapped expression data from samples containing variants 
that are predicted to cause defective splicing with control sam-
ples lacking these mutations. The program objectively evaluates 
each mutation with statistical tests that determine the likelihood 
of and exclude normal splicing. To our knowledge, no other soft-
ware currently validates splicing mutations with RNA-Seq data on 
a genome-wide scale, although many applications can accurately 
detect conventional alternative splice isoforms (i.e.29). Veridical is 
intended for use with large data sets derived from many samples, 
each containing several hundred variants that have been previously 
prioritized as likely splicing mutations, regardless of how the candi-
date mutations are selected. It is not practical to analyze all variants 
present in an exome or genome, rather only a filtered subset, due 
to the extensive computations required for statistical validation. As 
such, Veridical is a key component of an end-to-end, hypothesis-
based, splicing mutation analysis framework that also includes the 
Shannon splicing mutation pipeline10 and the Automated Splice Site 
Analysis and Exon Definition server5. There is a trade-off between 
lengthy run-times and statistical robustness of Veridical, especially 
when there are either a large number of variants or a large number 
of RNA-Seq files. As with most statistical methods, those employed 
here are not amenable to small sample sets, but become quite pow-
erful when a large number of controls are employed. In order to 
ensure that mutations can be validated, we recommend an excess 
of control transcriptome data relative to those from samples con-
taining mutations (> 5 : 1), guided by the power analysis described 
in Methods. We do not recommend the use of a single nor a few 
control samples to corroborate a putative mutation. Not surpris-
ingly, we have found that junction-spanning reads have the greatest 
value for corroborating cryptic splicing and exon skipping. Even a 
single such read is almost always sufficient to merit the validation 
of a variant, provided that sufficient control samples are used. For 
intron inclusion, both junction-spanning and read-abundance-based 
reads are useful and a variant can readily be validated with either, 
provided that the variant-containing experimental sample(s) show 
a statistically significant increase in the presence of either form of 
intron inclusion corroborating reads.
Veridical is able to automatically process variants from multiple 
different experimental samples, and can group the variant informa-
tion if any given mutation is present in more than one sample. The 
use of a large sample size allows for robust statistical analyses to be 
performed, which aid significantly in the interpretation of results. 
The main utility of Veridical is to filter through large data sets of 
predicted splicing mutations to prioritize the variants. This helps to 
predict which variants will have a deleterious effect upon the pro-
tein product. Veridical is able to avoid reporting splicing changes 
that are naturally occurring through checking all variant-containing 
and non-containing control samples for the predicted splicing con-
sequence. In addition, running multiple tumour samples at once 
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does this to search for disease-causing (non-splicing) variants and 
the Multivariate Analysis of Transcript Splicing (MATS)29 tool 
(among others) can be used for the discovery of alternative splicing 
events. However, in our case, in most instances the distribution of 
reads in a single sample is compared to the distributions of reads 
in the control set, as opposed to a likelihood framework-based 
approach. We are suggesting that our approach be coupled to exist-
ing approaches to act as an a posteriori, hypothesis-driven, check 
on the veridicality of specific variants.
While there is considerable prior evidence for splicing mutations 
that alter natural and cryptic splice site recognition, we were some-
what surprised at the apparent high frequency of statistically sig-
nificant intron inclusion revealed by Veridical. In fact, evidence 
indicates that a significant portion of the genome is transcribed36, 
and it is estimated that 95% of known genes are alternatively 
spliced32. Defective mRNA splicing can lead to multiple alternative 
transcripts including those with retained introns, cassette exons, 
alternate promoters/terminators, extended or truncated exons, and 
reduced exons40. In breast cancer, exon skipping and intron reten-
tion were observed to be the most common form of alternative 
splicing in triple negative, non-triple negative, and HER2 positive 
breast cancer41. In normal tissue, intron retention and exon skipping 
has been predicted to affect 2572 exons in 2127 genes and 50 633 
exons in 12 797 genes, respectively42. In addition, previous stud-
ies suggest that the order of intron removal can influence the final 
mRNA transcript composition of exons and introns43. Intron inclu-
sion observed in normal tissue may result from those introns that 
are removed from the transcript at the end of mRNA splicing. Given 
that these splicing events are relatively common in normal tissues, 
it becomes all the more important to distinguish expression patterns 
that are clearly due to the effects of splicing mutations — one of the 
guiding principles of the Veridical method.
Veridical is an important analytical resource for unsupervised, thor-
ough validation of splicing mutations through the use of compan-
ion RNA-Seq data from the same samples. The approach will be 
broadly applicable for many types of genetic abnormalities, and 
should reveal numerous, previously unrecognized, mRNA splicing 
mutations in exome and complete genome sequences.
Data availability
figshare: Input, output, and explanatory files for Veridical, http://
dx.doi.org/10.6084/m9.figshare.89497144.
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Veridical exome annotation input format
This input format can be generated via ConvertToExomeAnnotation.
pl. The file must be tab-delimited, excepting its header, which must 
be comma-delimited. It must have the following, case-insensitive, 
header columns, to which its data must adhere: transcript, chromo-
some, exon chr start, exon chr end, exon rank, gene. The column 
headers need only contain the given text (i.e. a column labeled 
gene_name would be sufficient to satisfy the above requirement 
for a “gene” column). The order of the columns is immaterial.
A few rows from a sample exome annotation file is provided below 
(text wrapped for readability):
Transcript ID,ID,ID,Chromosome Name,Strand,
Exon Chr Start,Exon Chr End,
Exon Rank in Transcript,Transcript Start,
Transcript End, Associated Gene Name
NM_213590 NM_213590 NM_213590 chr13 + 50571142
50571899 1 50571142 50592603 TRIM13
NM_213590 NM_213590 NM_213590 chr13 + 50586070
50592603 2 50571142 50592603 TRIM13
NM_198318 NM_198318 NM_198318 chr19 + 50180408
50180573 1 50180408 50191707 PRMT1
Veridical output
If a variant contains any validating reads, Veridical outputs the vari-
ant in question, along with some summary information and a table 
specifying the numbers of each validating read type detected for 
both the experimental and control samples. Within the output of 
Veridical, the phrase: “Validated (x) variant n times” means that the 
variant was validated mainly for splicing consequence x and has n 
validating reads. The variant will only appear within the *.filtered 
output file if the p-value for either junction-spanning or read-
abundance-based reads for splicing consequence x was statistically 
significant (defined, by default, as: p < 0.05). After the variant 
being validated is provided, along with its primary predicted splic-
ing consequence, the output is divided into two sections with iden-
tical contents: one for the experimental sample(s) and another for 
control samples. The summary enumerates the number of reads of 
each splicing consequence, partitioned by evidence type (junction-
spanning or read-abundance-based), and by sample type (tumour 
or normal for control samples, and only tumour for experimental 
samples). A table describing the number of each read type for every 
file follows this summary. An example of this output, for the variant 
within RAD54L, as shown by Figure 7 and the last portion of Table 2, 
is provided. While Veridical outputs this as plain text, with the table 
in a tab-delimited format, we provide this output as an Excel docu-
ment with descriptions of the meaning of each table heading, to clar-
ify the presentation of the data. All input and output files for the five 
variants presented are provided. VeridicalOutExample.xls 
contains the output for the variant within RAD54L, along with 
descriptions of the terms used and the output format. all.vin 
contains the input variant file. allTumoursBAMFileList.txt 
and allNormalsBAMFileList.txt are the BAM file lists 
for tumour and normal samples, respectively. all.vout con-
tains the Veridical output. The exome file can be retrieved using 
ConvertToExomeAnnotation.pl, available with the other 
programs at: www.veridical.org. The BAM file lists contain the 
TCGA file UUID, followed by a slash, followed by the file name. 
The RNA-Seq data itself can be downloaded from TCGA at: https://
tcga-data.nci.nih.gov/tcga/.
Veridical variant input format
This input format most easily accepts formatted output from the 
Shannon Pipeline. In particular, all variants of interest should be 
concatenated into a single file. Once a, tab-delimited, concatenated 
file has been generated, it can easily be formatted correctly by using 
FilterShannonPipelineResults.pl. All file headers must 
precisely match their outlined schema. One can also manually ensure 
the following: the header line has no quotation marks or special 
characters, empty columns have been replaced by a period (.) and 
each variant line contains only a single gene (comma-delimited 
gene lists must be split such that there is only one gene per line). 
If one wishes Veridical to consider variants pertaining to more than 
one experimental sample, a comma-delimited list of experimental 
samples, in the form of BAM file names, must be provided as the 
key column. The key column must always contain at least one file 
name that is present as the base name of one of the files listed in the 
BAM file list that must be passed to Veridical.
Alternatively, one can prepare the input format as follows. The header 
must contain at least the following, case-insensitive, values to which 
the file’s columns must adhere to: chromosome, splice&coordinate, 
strand, type, gene, location, location_type, heterozygosity, variant, 
input, key. The column headers need only contain the given text 
(i.e. a column labeled gene_name would be sufficient to satisfy 
the above requirement for a “gene” column). Column headers with 
ampersands (&) denote that all words joined by this symbol must 
be present for that column (i.e. Splice_site_coordinate 
satisfies the “splice&coordinate” requirement). The order of the 
columns is immaterial. The input column can contain any identi-
fier for the variant and need not be unique. The location column 
specifies if the site is natural or cryptic. For Veridical, all that mat-
ters is that cryptic variants contain the word “cryptic” as part 
of their value in this column and that non-cryptic variants do not. 
The location_type column is only used for cryptic variants 
and specifies if the variant is intronic or exonic. It is not currently 
used by the program. This column must be present but can always 
be set to null (i.e).
A few rows from a sample variant file is provided below (text 
wrapped for readability):
Chromosome   Splice_site_coordinate   Strand
Ri-initial Ri-final ΔRi Type Gene_Name Location
Location_Type Loc._Rel._to_exon
Dist._from_nearest_nat._site
Loc._of_nearest_nat._site  Ri_of_nearest_nat
Cryptic_Ri_rel._nat. rsID Average_heterozygosity
Variant_coordinate  Input_variant   Input_ID
RNASeqDirectory_ID RNA_Seq_BAM_ID_KEY
chr10 89711874 + 12.09 -2.62 -14.71 ACCEPTOR PTEN
NATURALSITE . . . . . . . . 89711873 A/G ID1 dir
file
chr10 89712017 + 5.18 -1.85 -7.03  DONOR  PTEN
NATURALSITE . . . . . . . . 89712018 T/C ID1 dir
file
chrX 9621719 + -4.78 2.25 7.03  DONOR  TBL1X
CRYPTICSITE EXONIC . 11 9621730  2.24  GREATER .
. 9621720 C/T ID1 dir file
Supplementary materials
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Figure S1. Histogram	and	embedded	Q-Q	plots	portraying	the	difference	between	untransformed	and	Yeo-Johnson	(YJ)	transformed	data.	
The	plots	depict	intron	inclusion	for	the	inactivating	mutation	(chr12:83359523G>A)	within	TMTC2, as shown in Figures	6(B)	and	6(C). The 
arrowheads	denote	 the	number	of	 reads	 in	 the	variant-containing	file,	which	 is,	 in	all	cases,	more	 than	observed	 in	 the	control	samples	
(p	<	0.01).	The	figure	legend	for	all	panels	is	provided	in	(G),	which	shows	that	blue	and	red	plot	elements	correspond	to	untransformed	
data,	while	 yellow	and	purple	 correspond	 to	YJ	 transformed	elements.	Dotted	 lines	 in	 the	Q-Q	plots	 are	 lines	passing	 through	 the	 first	
and	third	quantiles	for	a	normal	reference	distribution.	(A),	(C),	and	(E)	show	junction-spanning	based	reads,	while	(B),	(D),	and	(F)	show	
read-abundance-based	reads.	(A)–(B)	depict	tumour	sample	distributions,	(B)–(C)	depict	normal	sample	distributions,	and	(E)–(F)	depict	
combined	tumour	and	normal	sample	distributions.	This	figure	is	demonstrative	of	the	general	trend	we	have	observed.	Only	data	from	normal	
samples	resemble	a	Gaussian	distribution	and	the	YJ	transformation	greatly	improves	the	Gaussian	nature	of	all	distributions.
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correlating variation data with observations of (mis-)splicing patterns.
 
The program fulfils an important need in the community, the results appear promising and will be of
special interest to groups performing RNA-seq analysis in medical settings. I have only some minor
suggestions that the authors may like to consider.
 
 
Suggestions:
The explanation of the methodology is relatively difficult to follow, and I wonder if it might not be
better to simplify Figures 1 and 2 for didactic sake. For instance, in Figure 1A, it is unclear where
the location of variant  is. Does the curved line mean that it could be anywhere in the middle C
exon?  Also, I assume that exons are being shown in blue and reads shown in gray? 
Also, the legend text is overly complicated:  >  swap  and . While aficionados of first orderD E D E
logic will follow without problems, I would suggest that it would be better for didactic purposes to
delete this and to implicitly assume that <  for the sake of this figure. Figure 1B is confusing atD E
this point in the manuscript because the motivation for switching the variable , , , and  is notA B D E
yet clear. On the other hand, panel C and panel D are trivial and do not add anything. I would
suggest using Figure 1 to provide one concrete example one a simple level, and stating in the text
that the variables are to be switched if the candidate mutation is located on the other side of the
exon. 
Also, the explanations of the method that are couched in first order logic-like notation are difficult to
follow, because it is not stated whether the variant  can precede the start of the read (in whichC
case  would be negative). The subscripts for  in turn have the subscript s  but the variable  inC-S r 1 S
the formula does not. 
Although in the end, I think I follow the overall method, the reader is forced to make arbitrary
assumptions in order to interpret the formulae being used to explain the method. A similar
comment pertains to the flow chart in Figure 2.
Therefore, I would suggest the authors take some pains to improve the clarity of the explanation of
the method. I would suggest that they show one of two concrete examples and provide English
language specifications of the FOL-like formulae that describe the partitioning of reads.
 
I am a little unclear on the use of control samples vs experimental samples. Assuming the
experimental samples come from different individuals, what is the reason to assume that they will
have the same distribution of splice mutations?  And given that one finds dozens of splice variants
in normal individuals, what exactly is meant by a control sample? Will control samples not also
have lots of splice mutations? How does the method deal with this? And if we are dealing with
cancer samples, why not user a paired control to detect cancer-specific mutations? In light of this,
the statement "Maximizing the set of control samples, while computationally more expensive,
 does not appear to be supported byincreases the statistical robustness of the results obtained.",
evidence presented in the manuscript.
 
It would be interesting to see a comparison of the distribution of  values and results of Veridical Ri
analysis?
 
How does Veridical decide which sequence variant is causative if there are multiple variations
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How does Veridical decide which sequence variant is causative if there are multiple variations
located in the vicinity of a given mis-spliced exon? 
 
The mutation nomenclature chr1:985377 C>T should not have a space between the position and
the nucleotides.
 
It is unclear to me why a linear regression model was used to show the performance of the method.
The authors could provide timings from real runs.
 
It would be interesting to see a plot on the relationship of the p-values called by Veridical and the
sequencing depth covered. The authors state "In particular, a lack of sufficient coverage at a
particular locus will cause Veridical to be unable to report any significant results. A coverage of at
, but they do not provide evidence for this assertion. This is anleast 20 reads should be sufficient."
important question given that low-expressed genes are thus likely to be systematically
under-represented in the results of Veridcal, and this should be commented on somewhere in the
paper.
 
It would be good if the authors provided Sanger validation of at least some of the mis-splicing
events reported in the paper.
 
The input format for Veridical is described as "This input format most easily accepts formatted
 Why not allow VCF files and filter them for potential spliceoutput from the Shannon Pipeline."
variants informatically prior to Veridcal analysis? It was unclear to me how the variants are to be
selected and whether Veridical can be easily used outside of the Shannon pipeline?
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
1 Comment
Author Response
, Peter Rogan
Posted: 27 Mar 2014
We really appreciate your constructive comments. In particular, we have revised figure 1 as you
suggested. Furthermore, we have endeavored to clarify the methods by referencing every
corresponding equation pertaining to each informal description of a methodological principle. All
references to figures pertain to the first version of the manuscript.
 
"It is unclear to me why a linear regression model was used to show the performance of the
method. The authors could provide timings from real runs."
All data points in Figure 3 (a) consist of data from actual runs. We did not conduct a
sufficient number of large-scale runs to accurately determine performance and believe that
the regression model provides information for users who wish to use the software in that
context.
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context.
 
"The input format for veridical is described as “This input format most easily accepts
formatted output from the Shannon Pipeline.” Why not allow VCF files and filter them for
potential splice variants informatically prior to veridcal analysis? It was unclear to me how
the variants are to be selected and whether veridical can be easily used outside of the
Shannon pipeline?"
 
It would be prohibitively difficult for a user and cumbersome to attempt to add such support.
The Shannon Pipeline and most other splicing analysis software accept variant call format
(VCF) input and outputs their own custom format. VCF is very poorly suited for the
annotation of detailed splicing information. The position of the variant is not necessarily the
same as the affect splice junction coordinate. While it is possible to label the junction using
custom fields in the VCF “INFO” column, the format is not standardized; it would be specific
to the particular software used, and thus provides no real advantage over the Shannon
pipeline output.
This would become feasible if the community were to agree upon a standard definition of
custom fields; this concept could be generalized to other scenarios in which both a variant
and one (or more) other associated coordinates (in this case, a splice site, but elsewhere,
perhaps the site of some specific interaction). This process would ultimately require an
explicit definition of the content and schema for such additional fields, and would need to
solicit views from the community to ensure widespread adoption. We would be interested in
contributing to this endeavor.
"It would be interesting to see a plot on the relationship of the p-values called by Veridical
and the sequencing depth covered."  
We have conducted a preliminary comparison of p-values for specific evidence types and
splicing consequences vs. coverage per exonic base (the coverage of the gene divided by
the length of the pertinent exon) and found that the results were quite difficult to interpret.
We suspect that this could be explained by the fact that, due to significant intron inclusion,
normalizing by exonic length is not really appropriate. Cryptic sites and alternative splicing
make direct comparison of these values difficult to compute.
 
"How does Veridical decide which sequence variant is causative if there are multiple
variations located in the vicinity of a given mis-spliced exon?"
Veridical does not currently address cases in which multiple independent variants pertain to
the same splice site. In such a case, each variant is analyzed independently.  Based on
Mendelian disorders, we have rarely observed multiple independent variants alter the
strength of the same splice site, and in any case, the phase of these variants is unknown, so
they could reside on different chromosomes. 
 
"I am a little unclear on the use of control samples vs experimental samples. Assuming the
experimental samples come from different individuals, what is the reason to assume that
they will have the same distribution of splice mutations? And given that one finds dozens of
splice variants in normal individuals, what exactly is meant by a control sample? Will not
control samples also have lots of splice mutations? How does the method deal with this?
And if we are dealing with cancer samples, why not user a paired control to detect
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And if we are dealing with cancer samples, why not user a paired control to detect
cancer-specific mutations? In light of this, the statement “Maximizing the set of control
samples, while computationally more expensive, increases the statistical robustness of the
results obtained.“ Does not appear to be supported by evidence presented in the
manuscript."
Control samples consist of all non-variant containing (NVC) tumour samples (relative to the
variant being analyzed) and normal samples. In the examples shown in the paper, we
maximized the number control samples used (106 normal samples and, in general, over
400 NVC samples). Control samples do indeed contain splicing mutations and this is a
strength of our statistical paradigm. We term them control samples, because we consider
their read distribution to correspond to that expected from the null hypothesis, as they do
not contain the specific variant in question. The “noise” introduced by these splicing variants
in control samples ensures that we are testing the variant containing samples against
samples with many, distinct, splicing mutations. Thus, the greater the number of samples,
the smaller the batch effects, which makes the method more reliable. While the normal and
tumor DNA sequencing data was paired to call somatic variants, we do not require paired
controls for the RNA-Seq data. In fact, TCGA does not provide such data. Since we initially
designed the software for the task of analyzing their dataset, we did not wish to assume that
paired RNA-Seq data was available.
 
"It would be good if the authors provided Sanger validation of at least some of the
mis-splicing events reported in the paper."
We do not have access to the TCGA tumour samples used. While TCGA performed Sanger
validation of a small subset of their variants, none of the variants validated by Veridical had
any associated Sanger sequencing data.
 
"It would be interesting to see a comparison of the distribution of Ri values and results of
Veridical analysis?"
The variants predicted by the Shannon splicing mutation analysis pipeline exhibit changes
in information content (ΔR ). The change in information content of a splice site is directly
related to the thermodynamics of the binding event  and therefore the(Schneider, 1997)
strength of the splice site ( ; ). Therefore, one wouldRogan  1998et al., Rogan , 2003et al.
expect ΔR  to be highly predictive of valid splicing variants, where cryptic sites are expected
to result in increased splice site strength, and natural sites would be expected to be
weakened.
The median ΔR for cryptic variants in the set of pre-Veridical variants (those variants called
as somatic mutations and predicted by the Shannon Pipeline to affect mRNA splicing) was
2.6 bits, while the median for validated variants was 2.38 bits. For non-cryptic variants the
pre- and post-validation median ΔR  values were -2.52 and -3.18 bits, respectively.
The information content of cryptic variants actually decreased slightly in the validated set.
This likely is related to other factors, such as the initial strength of the natural site and the
exon length, which are not accounted for by this analysis. However, the average information
content of natural sites did decrease, as expected. The reason for the decrease not being
more substantial, again, is likely due to the involvement of other factors, such as the
distance of the variant to the natural site – which impacts its R  value. We have refrained
i
i
i 
i
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distance of the variant to the natural site – which impacts its R  value. We have refrained
from including this discussion in the manuscript, since there is no requirement  forper se
Veridical to be used with the Shannon Pipeline. An explicit definition of the required input
format is provided in the paper.
 No competing interests were disclosed.Competing Interests:
 Liliana Florea
McKusick-Nathans Institute of Human Genetics, Johns Hopkins University, Baltimore, MD, USA
Approved with reservations: 07 March 2014
 07 March 2014Referee Report:
The authors describe a method and the associated software, Veridical, for assessing the effects on
pre-mRNA splicing of predicted splicing-affecting mutations. To do so the program compares splicing
effects, measured by the supporting read counts, in variant-containing (disease) samples against a
distribution derived from very large numbers of 'normals', either normal tissue from the same individual or
samples from healthy individuals.
The idea is ingenious and novel as applied to mutations affecting splicing, although not in general (see 
 [ ], which exploits the availability of large numbers of samples to identify likelyVAAST Yandell et al. 2011
deleterious variants; it is also the premise for the  and  projects). The software isHapMap 1000 Genomes
fast and practical, being able to test thousands of variants in hundreds of samples within hours. This is the
first software of its kind, and if accurate it will be a very valuable resource for clinical genomics.
That being said, while the article provides proof-of-concept and clearly demonstrates the potential of the
tool with specific examples, there are several missing pieces that are needed to provide the readers with
a view of its overall performance and limitations and to help them use it effectively.
Major comments:
The article shows numerous positive examples, however there is no indication of the tool's
performance in general. The authors should include the results from running the tool on a full data
set, to give potential users an idea of the expected outcome.
Also, several other tools (e.g., , , ) have been developed for the relatedMATS Miso SpliceTrap
problem of discovering alternative splicing events and comparing them among samples. MATS in
particular, allows differential splicing analyses with multiple replicates. Ideally the paper would
include a comparison with MATS on the data set analyzed; this comparison is informative even if
MATS is used with only a subset of the samples.
 
The method uses the YJ-transformed distribution of supporting read counts across the 'normals' to
determine a p-value for the variant, and thus judge its significance and impact on splicing. This is
an interesting concept that assumes that with large numbers of 'normals' sample and batch effects
will even out; hence, large numbers of samples are required to ensure accuracy. Since these are
absolute (non-normalized) counts, however, the method may not work if the variant sample is
obtained with a different method, e.g. by rRNA depletion of total RNA whereas most normal
samples would come from polyA+ libraries. The authors should clearly discuss this and other
possible limitations of their approach.
i
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samples would come from polyA+ libraries. The authors should clearly discuss this and other
possible limitations of their approach.
 
Related to the above, the authors mention on several occasions the difficulty in identifying intron
inclusion (II) events, in particular the large number of false positives. Indeed, IIs are generally
difficult to predict due to the presence of intronic reads ('noise') from unspliced RNA. The levels
can vary from sample to sample and across the genome, depending on the sample preparation,
gene expression level, splicing efficiency, etc. By comparing read counts exclusively among
samples and without taking into account the gene- or genome-level background, Veridical is likely
to produce many false positives.
In particular, the 14 supporting reads in the left intron on Figure 4 seem hardly sufficient to indicate
an II event, all the more as there is a larger number of reads in the neighboring intron (not predicted
to be II). The authors should provide other type of evidence for this event.
 
The mathematical formulas for the various classes of supporting reads and their locations (page 4,
continued on page 6) are hard to understand. It would greatly help the readers to include a figure
showing schematically the event and read location with respect to the introns and exons.
Minor comments:
As another reviewer pointed out, the software requires a registration to obtain a temporary license
for 30 days, after which the availability and terms of use are unclear. This mode of distribution is
not a problem, but the terms should be clearly stated in the manuscript. Also, this is a stand-alone
software and not a web tool as implied by the article.
 
The authors use the term 'cryptic' splice sites throughout the manuscript (I assume meaning
'aberrantly activated'), but some of the events discovered could be alternative exon ends. It would
be helpful to clarify in the context.
This is a potentially very powerful and useful tool. I gave the article an 'Approved with reservation'
because it is critical to include results in the aggregate to complement the showcased examples, as well
as to discuss its limitations. I will gladly change once these few issues are addressed.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
 No competing interests were disclosed.Competing Interests:
1 Comment
Author Response
, Peter Rogan
Posted: 27 Mar 2014
We greatly appreciate your remarks and useful suggestions. All references to figures pertain to the
first version of the manuscript.
 
First, we address your comments regarding VAAST and  exome annotation softwarede novo
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First, we address your comments regarding VAAST and  exome annotation softwarede novo
packages. VAAST uses a feature-based, maximal likelihood, approach to  variantsidentify
suspected to be pathogenic. While  present a general, and indeed very usefulYandell et al.
method, it is very different from Veridical in two key respects. Most importantly, Veridical does not
aim to identify putatively pathogenic variants, but rather, to  existing  predictionsconfirm in silico
thereof. Although it is not designed for this purpose, one could envision using the likelihood
approach used by VAAST to extract solely splicing variants, annotating them, and then confirming
these variants using Veridical with corresponding RNA-Seq data (assuming such data exists).
Veridical is the only software available for statistical validation of splicing mutations. While both
programs prioritize variants, their goals are rather dichotomous. Similarly, Veridical depends upon
the use of an (ideally conservative) exome annotation. We do infer exon skipping events (i.e.
alternative splicing) , but only to catalog dysregulated splicing “phenotypes” due tode novo
genomic sequence variants. Since we rely upon existing annotations, improvements in this area
will serve to benefit Veridical and complement it well. In many ways, our parsimonious approach
was possible precisely because the problem we address is quite a lot easier to address than de
 alternative splicing inference. We are not suggesting that Veridical be used to analyze allnovo
variants, resulting from exome or whole-genome sequencing experiments. The Shannon Pipeline,
which predicts candidate variants, contains several default or modifiable filters which can limit the
number of candidates input to Veridical. We are suggesting that our approach be coupled to
existing approaches to act as an , hypothesis-driven, check on the veridicality ofa posteriori
specific variants.
 
We consider alternative splicing to be a different problem, for the following reasons. The authors
state: “MATS calculates a -value for each exon isoform by comparing the observed posteriorP
probability with a set of simulated posterior probabilities from the null hypothesis.” We do not
simulate posterior probabilities; we calculate them directly from the distribution of control samples,
which represent the null hypothesis. Further, MATS requires the user to set uniform thresholds for
all alternative splicing events, which in our case, may vary between variants (i.e. inactivating
versus leaky mutations). Finally, neither MATS, nor Miso or SpliceTrap provide any means of
analyzing novel isoforms created by the activation of cryptic splice sites.
 
We appreciate your insightful summary of our underlying statistical methodology and appreciate
the limitations of our statistical inference method. It is certainly the case that the use of different
RNA-Seq protocols could prove problematic. Veridical is intended to be used with RNA-Seq data
from the same individual as matched DNA-Seq data. We assume that the control RNA-Seq data
are generated with comparable sequencing protocols. This has been articulated in the Discussion.
 
We agree that levels of intron inclusion and alternative splicing can be highly variable across
samples, due to factors extrinsic to the mutation itself. Such variability is a significant contributory
factor to the production of transcriptomic “noise”. Given that statistically significant levels of intron
inclusion were observed across all control samples, the prevalence of adjacent intron inclusions
(which is not uncommon, se), does not weaken the inference that the predicted splicingper 
mutation increases the levels of intron inclusion.  However, in such cases, the statistical threshold
to achieve significance would be higher. A recent analysis indicates that p-value thresholds of
0.005 to 0.001 are appropriate ( ). Our statistical approach tacitly accounts for thisJohnson, 2013
and indeed greater levels of such “noise” could actually increase the statistical utility of our
computation. Because of a wide degree of variation of intron inclusion in both normal and tumor
transcriptomes, we deliberately elected against normalizing gene level expression in the program.
 
Regarding the specific example cited, the 14 intronic reads in the sample containing the variant  in
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Regarding the specific example cited, the 14 intronic reads in the sample containing the variant  in
the read-abundance category (Figure 4 (A)) are contrasted with the per sample mean of 4.051
reads across all non-variant-containing tumours and normal samples in this intron (i.e. the totality
of control samples, which results in a p-value of 0.04. We agree that this is not a strong result, and
would not permit us to reject the null hypothesis had the threshold significance level been reduced
to ≤ 0.01 (which the user is free to stipulate).In this particular case, the variant is still strongly
validated, due to the presence of junction-spanning, exon skipping reads (that are absent from all
of the control samples). We do not stipulate that the predicted mutation have only one abnormal
read type, but rather, that the test assesses each consequence separately. We suggest that the
corroborating evidence be taken together in support of variant-induced missplicing. Furthermore,
junction-spanning exon skipping is, in general, rarer than intron inclusion in these data.
Nevertheless, we do show examples of read-abundance tests for intron inclusion that achieve a
significance level of < 0.01, such as within  in Figure 6(C). As you point out, intron inclusionTMTC2
patterns also vary by intron and there are a large number of such intron inclusion reads in the
downstream intron in Figure 4(A). However, in our entire set of predicted splicing mutations, we did
not find any pertaining to the intron between exons 12 and 13. The observed increased intron
inclusion between exons 12 and 13 may be related to the weak (5.2 bit) donor (5’) splice site in
exon 12.  In fact, substantial intron inclusion was expected in intron 11, due to the minimal strength
of the exon 11 donor of 2.1 bits.
 
Regarding the comment concerning cryptic sites, we always mean non-canonical splice sites
activated by sequence-level variation, which are distinctly different from tissue-related alternatively
spliced isoforms lacking one or more constitutive exons. We and others have reported numerous
examples of common SNPs inducing cryptic splice site activation, which could result in the
annotation of accordingly altered transcripts.
 
It is unfortunate that Veridical had to be categorized as a “web tool”. We would have preferred to
indicate that the program is a standalone-tool.  does not provide this category,F1000Research 
even though other standalone programs have been published by the journal with the Web Tool
designation. In the Web Tools category, the journal guidelines require that we provide a set of
examples (complete with input and output files) representing the range of results that are obtained
with the software. Therefore, providing a full analysis of the complete TCGA breast cancer dataset
is beyond the scope of this paper.  It will be presented elsewhere.
 
We believe that the statements in the manuscript's conflict of interests section are sufficient to
describe the terms of use. We have added the requested details on , both indicatingVeridical.org
its duration and instructions for obtaining longer-term access to this software. 
 No competing interests were disclosed.Competing Interests:
 Francesc Xavier Roca
Division of Molecular Genetics and Cell Biology, Nanyang Technological University, Singapore,
Singapore
Approved: 28 January 2014
 28 January 2014Referee Report:
This manuscript describes a new computational tool named Veridical, which detects mutant-allele specific
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This manuscript describes a new computational tool named Veridical, which detects mutant-allele specific
splicing changes from large RNAseq datasets. This outstanding tool appears very useful to screen the
wealth of transcriptomic data for effects in splicing due to mutations in disease samples, and I think that it
will potentially be of interest for many if not all such RNAseq-based studies. In addition, this could spur
further efforts to derive similar tools with improved efficiencies. Use of this method should help establish
the importance of aberrant splicing in disease as well as the effects of genomic mutations at the RNA
level. I only have two comments, that do not diminish my overall rating of this work as of high value:
 
I personally disagree with the widespread use of the word “validation” in the title, abstract and text.
Authors describe Veridical as a tool to “validate” DNA sequence variants that alter splicing. Indeed,
I think that this tool provides an “association” between the variants and splicing, but not a formal
proof of their connection. As the genomic and RNA samples usually come from different individuals
with many confounding variables, the possibility that the splicing changes arise from factors other
than the individual DNA mutations cannot be ruled out. In other words, changes in the levels of
trans-acting splicing factors could account in part or totally for the splicing changes across
samples. The statistical tests properly conducted in Veridical are designed to minimize such
possibility but do not rule it out. In addition, the inherent noisy nature of RNAseq datasets also
prompts for caution in the conclusions. To me, the direct proof that a DNA mutation changes
splicing of its pre-mRNA can only be provided using minigenes and cell transfection (or in vitro
splicing), in which the substrate sequences and cellular context are under almost absolute control.
Indeed, the Veridical method is reminiscent of GWAS (Genome-Wide Association Studies), in
which the genotype in the DNA, wild-type or mutant, is associated to its phenotype, such as normal
versus disease (or other traits) in GWAS, or normal versus aberrant splicing in this study. Thus, for
me Veridical provides strong associations – but not validations – between DNA mutations and their
effects on splicing.
 
As mentioned briefly at the beginning of Discussion, Veridical has built-in prediction tools to
prioritize the mutations that are more likely to affect splicing, such as those mapping to splice sites.
Even if other sources and tools are cited, a more extensive explanation of these components of
Veridical would help the reader/user.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
1 Comment
Author Response
, Peter Rogan
Posted: 27 Mar 2014
We greatly appreciate your review of this paper.
 
Regarding our use of the term “validation”, we understand that  validation is not comparablein silico
to  or  validation assays. That said, we would like to elaborate. The DNA and RNAin vitro in vivo
samples were matched from the same individual, which is not the case for many  assays, i.e.in vitro
mini-gene expression analysis by reverse transcription followed by PCR. The very large set of
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mini-gene expression analysis by reverse transcription followed by PCR. The very large set of
controls used in our analysis is also atypical in experimental validation of proposed mutations. 
When results are obtained that are statistically significant, it is conventional to refer to them as
“validating”. Even if DNA-Seq and RNA-Seq data were not matched from the same individual,
Veridical would still determine if known splicing mutations were expressed in a known subset of
tumors, however we would instead refer to this as "corroborating".
The comparison with GWAS is inappropriate: we are not comparing means of distinct case and
control distributions; rather we are computing the read distribution from the control samples and
determining the probability that the mutation bearing sample falls within that distribution.
Additionally, the initial hypothesis in a GWAS is quite vague. Thus, the resultant associations are
not of the same category as those provided by Veridical. While Veridical does indeed validate the
splicing consequence observed, when we say that it validates the mutation we do only mean that it
strongly corroborates the mutation as a causative agent of the splicing consequence. The
responsibility to decide if the p-value reported by the program is sufficient is left up to the user, who
should avoid incorrect arguments.post hoc ergo propter hoc 
 
Our reference to prioritization of variants for subsequent verification is based upon the result of
Veridical's statistical tests. We explicitly mention that the software is not well suited for the analysis
of raw output from genome-scale analyses, and that filtering should be performed , as we a priori
conducted, with a separate Perl script, which is available with Veridical. 
 No competing interests were disclosed.Competing Interests:
 Stefania Bortoluzzi
Department of Biology, University of Padova, Padova, Italy
Approved with reservations: 27 January 2014
 27 January 2014Referee Report:
The paper “ ” byValidation of predicted mRNA splicing mutations using high-throughput transcriptome data
Viner . presents Veridical, a new software for the interpretation and validation of genetic variantset al
identified by DNA sequencing that alter mRNA splicing, leveraging RNA-seq data. The method is based
on statistical comparisons of the normalized read counts of abnormally-spliced RNA species in mutant
versus non-mutant tissues.
 
Actually, the interpretation of genetic variants is a difficult and key issue in current research.
The integration of genomic and transcriptomic data, namely the use of RNA-seq-based transcriptome
characterization as a “molecular phenotype” of cells is useful and meaningful.
 
The software is standalone (not a web-tool) and it is completed by perl scripts, facilitating data
management.
The manuscript declare that “Veridical and its associated software programs are available at:
www.veridical.org”.
Actually, Veridical is commercially available to the scientific community. A trial version lasting 30 days can
be downloaded by the website, but in order to obtain binaries, the website requests a registration with an
institutional email address - they reserve the right to deny access to users who register with third-party
mail servers (Gmail, Yahoo, Hotmail, etc.).
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mail servers (Gmail, Yahoo, Hotmail, etc.).
No pricing information is included in the manuscript and, more importantly, in the webpages accessible to
download the software, either before or after registration.
After downloading the software, I was not able to find R scripts that can be useful to generate some plots,
as indicated in the manuscript.
 
Saying that, the paper is written in a clear language and it is quite complete.
I propose a few revisions that in my opinion can improve the manuscript readability and clarity.
Introduction
 
Line 13 (minor): indicate which hereditary disease (colon cancer?).
 
Methods
 
2  Par, Line 5 (minor): “Maximising” is used, but probably the meaning is “increasing” (the number
of).
 
Figure 1 (major): I feel that the info provided by points C and D is trivial, whilst point A's images,
sentences and legends can be improved. Figure 1 C and D shows simply examples of reads that
are mapped continuously and discontinuously to the reference genome. I think that every potential
user of this type of software known well this concept. On the other hand, regarding A and B (upper
part of the figure) there is not clear correspondence between the text in the legend and the image,
and between the image and the text below (the arch overlap the point A in the figure B, whereas
the text says "reads between A and B").
 
In general, in many cases in the manuscript, the correspondence between legend and figure can
be improved, by indicating more clearly the points specific sentences in the legend refer to.
Regarding this issue, for instance in Figure 4 I can see indicated neither the “exon 12” nor the “14
reads” mentioned in the legend. Please indicate (using colors, boxes, arrows or overlapping text)
key elements in the figure, and revise all figures using the same criterion.
 
Page 5 (minor): Consider revising the sentence “Furthermore, this transformation allowed us to
avoid the use of non-parametric testing, which has its own pitfalls regarding assumptions of the
underlying data distribution”, since normally it is assumed that parametric tests ground on
assumptions on data distributions, but non-parametric tests by definition can be used without
information about data distribution.
 
End of the next paragraph (major): “It is important to realize, therefore, that the p-values given by
Veridical are much more robust when the program is provided with a large number of samples.”
This is a pretty clear concept. Please, indicate a general rule to the user/reader: How many
samples are required? Setting a reasonable minimum can be more useful for experimental design
than saying the larger the sample size the most robust the result.
 
nd
Page 29 of 33
F1000Research 2014, 3:8 Last updated: 09 MAY 2014
F1000Research
1.  
2.  
 
Results
 
I have two important criticisms about the Results section:
The section is not organized in paragraphs, and mixes performance info (run time using different
number of samples and variants) with example results.
 
Not clearly saying how these results were obtained. This is important to guarantee repeatability.
 
(Major) I propose to reorganize the results (considering skipping less important examples; retain
surely Fig. 4 and 6) and insert a first paragraph providing information about the dataset used for
variants validation (how many samples, how many controls) and about the variant calling (BAM
files can be obtained with different settings and criteria and the same apply to calling and filtering of
variants). Moreover, please explain how RNA-seq data are treated, and particularly how they are
normalized to guarantee cross-samples comparability.
 
(Major) Also, a brief discussion about the impact of disease samples not carrying the given
mutation can be useful, as well as regarding the possibility that a tumour sample not carrying the
considered variant can present altered transcriptome since other variants (or factors) impact on the
“molecular phenotype”.
 
Figure 4 (minor): Please comment about the possible existence of intronic transcripts (totally
unknown or also annotated in Ensemble, but not displayed in the more conservative RefSeq
annotations).
 
Figure 5 (minor): Please define better the measure “Read−Abundance Total Intron Inclusion”.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
 No competing interests were disclosed.Competing Interests:
1 Comment
Author Response
, Peter Rogan
Posted: 27 Mar 2014
Thank you for your constructive comments. Regarding the R program, it is embedded within a Perl
script to facilitate expeditious parameter and data parsing. All of our figures were generated using
the Perl script, which, in-turn, invokes the R script. The program used to generate the histograms is
called: VeridicalHist.pl. The invocations of this program are provided in the Perl program
documentation on . We have clarified this in the revision of the manuscript. Wewww.veridical.org
will update this web page to include pricing information and details about trial access to the
software.
 
The requirement to provide an institutional email address is quite ubiquitous across a number of
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The requirement to provide an institutional email address is quite ubiquitous across a number of
academic disciplines, including many fields of informatics. In bioinformatics, for example,
ANNOVAR requires non-profit users to register an address and HGMD does as well. ChemAxon,
software for cheminformatics requires this. In astroinformatics, Sloan Digital Sky Survey III
(SDSSIII) also requires an institutional email. These examples are represent a fraction of the
numerous scientific websites that request such emails.  We consider it a professional courtesy to
provide legitimate email information, and reserve the right to disapprove addresses of individuals
who seek to mask their identity, which may enable them to avoid acknowledging the provenance of
the software.
 
We specifically address each of your other comments below. All references to figures pertain to the
first version of the manuscript.
 
"Line 13 (minor): indicate which hereditary disease (colon cancer?)."
López-Bigas . (2005)et al  conducted a general analysis using the complete sets of
SwissProt genes and OMIM known disease genes. Their mathematical model does not
depend upon any specific hereditary disease. Nevertheless, certain genes have been
demonstrated to exhibit very high frequencies of splicing mutations ( , ).ATM NF1
 
"2  Par, Line 5 (minor): “Maximising” is used, but probably the meaning is “increasing” (the
number of)."
This has been corrected.
 
"Figure 1 (major): I feel that the info provided by points C and D is trivial, whilst point A's
images, sentences and legends can be improved. Figure 1 C and D shows simply examples
of reads that are mapped continuously and discontinuously to the reference genome. I think
that every potential user of this type of software known well this concept. On the other hand,
regarding A and B (upper part of the figure) there is not clear correspondence between the
text in the legend and the image, and between the image and the text below (the arch
overlap the point A in the figure B, whereas the text says "reads between A and B")."
This has been revised accordingly.
 
"In general, in many cases in the manuscript, the correspondence between legend and
figure can be improved, by indicating more clearly the points specific sentences in the
legend refer to. Regarding this issue, for instance in Figure 4 I can see indicated neither the
“exon 12” nor the “14 reads” mentioned in the legend. Please indicate (using colors, boxes,
arrows or overlapping text) key elements in the figure, and revise all figures using the same
criterion."
In general, we provide exon numbers for reference and to allow for future exon identification.
While we specifically describe in the captions which exon contains the variant and relate this
to the exon number, we agree that graphical indications of key figure elements within IGV
screenshots could improve the clarity. These figures have been revised accordingly.
 
"Page 5 (minor): Consider revising the sentence “Furthermore, this transformation allowed
us to avoid the use of non-parametric testing, which has its own pitfalls regarding
assumptions of the underlying data distribution”, since normally it is assumed that
nd
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assumptions of the underlying data distribution”, since normally it is assumed that
parametric tests ground on assumptions on data distributions, but non-parametric tests by
definition can be used without information about data distribution."
In this sentence, we are not referring to the ubiquitous assumption of an underlying normal
distribution, which is indeed not required for non-parametric tests. Instead, the reference is
to, other, lesser known, assumptions that are tacit in most non-parametric methods. The
citation we provide (Johnson, 1995) refutes the commonly-held notion that non-parametric
tests make no assumptions about the underlying data distribution, and describes numerous
pitfalls that can occur when using non-parametric methods. For example, the author
articulates a particular assumption implicit in a comparison of means via the Mann-Whitney
test which actually requires that, “the two distributions are identical, in shape and scale,
differing only in their means. This assumption can be harder to justify than the asymptotic
normality demanded by the  test, and is rarely evaluated.”t
 
"End of the next paragraph (major): “It is important to realize, therefore, that the p-values
given by Veridical are much more robust when the program is provided with a large number
of samples.” This is a pretty clear concept. Please, indicate a general rule to the
user/reader: How many samples are required? Setting a reasonable minimum can be more
useful for experimental design than saying the larger the sample size the most robust the
result."
The revised manuscript describes the procedure and criteria for determining the number of
control samples needed.
 
"The section is not organized in paragraphs, and mixes performance info (run time using
different number of samples and variants) with example results."
The profiling information and example results are more clearly demarcated in the revision.
 
"(Major) I propose to reorganize the results (considering skipping less important examples;
retain surely Fig. 4 and 6) and insert a first paragraph providing information about the
dataset used for variants validation (how many samples, how many controls) and about the
variant calling (BAM files can be obtained with different settings and criteria and the same
apply to calling and filtering of variants). Moreover, please explain how RNA-seq data are
treated, and particularly how they are normalized to guarantee cross-samples
comparability."
We now elaborate upon experimental protocols, processing, and data providence. The
details of the RNA-Seq data and BAM file generation can obtained from the TCGA
consortia, which generated them, specifically in the supplementary methods of Koboldt et
. All of our data input directly into Veridical are available, and even the program (2012)al.
used to generate the histograms is provided. This ensures that all of our results are
reproducible.
The input data were obtained by analyzing the original TCGA dataset with the Shannon
pipeline, as the paper describes. The pipeline has been published in a peer-reviewed
context and is also available on a trial basis.  The details of the TCGA analytical results
obtained with the Shannon pipeline are considerable in length, putting them beyond the
scope of this paper and will be described elsewhere.
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scope of this paper and will be described elsewhere.
The journal guidelines concerning “web tools” state: “The article should provide examples of
suitable input data sets and include an example of the output that can be expected from the
tool and how this output should be interpreted.”  The examples shown are representative of
the splicing analysis outcomes present in the full TCGA analysis.  The examples provided in
this paper were designed to illustrate the capabilities of Veridical and are not an attempt to
forge biological conclusions of this large dataset.
 
"(Major) Also, a brief discussion about the impact of disease samples not carrying the given
mutation can be useful, as well as regarding the possibility that a tumour sample not
carrying the considered variant can present altered transcriptome since other variants (or
factors) impact on the “molecular phenotype”."
We provide in Table 2 the read counts for non-variant containing tumour samples, and for
the variant containing samples. We acknowledge that cancer gene expression results in a
gross dysregulation of mRNA splicing thereby causing the presentation of the altered
transcriptome. This was a motivating factor behind our choice of statistical method.
 
"Figure 4 (minor): Please comment about the possible existence of intronic transcripts
(totally unknown or also annotated in Ensemble, but not displayed in the more conservative
RefSeq annotations)."
If such exons exist, which are annotated as introns by RefSeq, and are actively transcribed
in normal or breast cancer tissues, the large number of control samples will reflect this and
such events will accordingly not trigger statistically significant intron inclusion events. We
have added a comment to the Discussion reflecting this.
 
"Figure 5 (minor): Please define better the measure “Read−Abundance Total Intron
Inclusion”."
This has been addressed in the revision.
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